Department of Molecular Biotechnologies and Health Sciences, Division of Haematology, University of Torino, Torino, Italy.
AOU "Città della Salute e della Scienza di Torino", Torino, Italy.
Hematol Oncol. 2022 Aug;40(3):332-340. doi: 10.1002/hon.2982. Epub 2022 Mar 9.
The pivotal role that ibrutinib plays in the management of Waldenström macroglobulinemia (WM) is undisputed but there are ongoing questions regarding its positioning in the therapeutic algorithm of WM as well as in some peculiar clinical situations. A panel of experts from Italy was convened to provide real world recommendations on the use of BTK inhibitors in lymphoproliferative diseases in general, and in patients with WM in particular. This position paper represents the panel's collective analysis, evaluation, and opinions and is made up of a series of questions frequently asked by practicing clinicians and answers based on currently available evidence.
伊布替尼在华氏巨球蛋白血症（WM）治疗中的关键作用毋庸置疑，但在 WM 治疗方案以及某些特殊临床情况下，伊布替尼的定位仍存在一些争议。意大利专家组受邀就 BTK 抑制剂在各种淋巴增殖性疾病，特别是 WM 患者中的应用提供真实世界的建议。本立场文件代表专家组的集体分析、评估和意见，由临床医生经常提出的一系列问题和基于现有证据的答案组成。
